BRTX Stock Analysis: Buy, Sell, or Hold?
BRTX - BioRestorative Therapies, Inc. Common Stock (NV)
$0.26
-0.03 (-10.94%)
▼
5d:
-19.03%
30d:
+15.89%
90d:
-76.37%
WAIT
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 13, 2026
Get Alerted When BRTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BRTX is down 19.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BRTX is down 19.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BRTX is currently trading at $0.26, which is considered fair relative to its 30-day fair value range of $0.22 to $0.29.
Technical Outlook: Technically, BRTX is in a strong downtrend. Immediate support is located at $0.22, while resistance sits at $0.33. Short-term momentum is weak, with the stock down 10.9% recently.
Market Sentiment: BRTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.50 (+3096.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BRTX is in a strong downtrend. Immediate support is located at $0.22, while resistance sits at $0.33. Short-term momentum is weak, with the stock down 10.9% recently.
Market Sentiment: BRTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $9.50 (+3096.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$0.22 -
$0.29
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
81.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.9%)
- BULLISH: Trading 3096.5% below Wall St target ($9.50)
- WARNING: Recommendation downgraded due to -19.0% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$0.22 -
$0.29
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$0.22
Resistance Level
$0.33
Current Trend
Strong Downtrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.25
Wall Street Target
$9.50
(+3096.5%)
Revenue Growth (YoY)
-94.9%
Share & Embed Analysis
Last updated: March 30, 2026 4:32 PM ET
Data refreshes hourly during market hours. Next update: 5:32 PM
Data refreshes hourly during market hours. Next update: 5:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BRTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 54 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 51 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 50 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 44 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 54 HOLD |
